Online citations, reference lists, and bibliographies.
← Back to Search

Bevacizumab For Newly Diagnosed Pleural Mesothelioma In The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-label, Phase 3 Trial

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, French Cooperative Thoracic Intergroup
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial growth factor is a key mitogen for malignant pleural mesothelioma cells, therefore targeting of vascular endothelial growth factor might prove effective. We aimed to assess the effect on survival of bevacizumab when added to the present standard of care, cisplatin plus pemetrexed, as first-line treatment of advanced malignant pleural mesothelioma. METHODS In this randomised, controlled, open-label, phase 3 trial, we recruited patients aged 18-75 years with unresectable malignant pleural mesothelioma who had not received previous chemotherapy, had an Eastern Cooperative Oncology Group performance status of 0-2, had no substantial cardiovascular comorbidity, were not amenable to curative surgery, had at least one evaluable (pleural effusion) or measurable (pleural tumour solid thickening) lesion with CT, and a life expectancy of >12 weeks from 73 hospitals in France. Exclusion criteria were presence of central nervous system metastases, use of antiaggregant treatments (aspirin ≥325 mg per day, clopidogrel, ticlopidine, or dipyridamole), anti-vitamin K drugs at a curative dose, treatment with low-molecular-weight heparin at a curative dose, and treatment with non-steroidal anti-inflammatory drugs. We randomly allocated patients (1:1; minimisation method used [random factor of 0·8]; patients stratified by histology [epithelioid vs sarcomatoid or mixed histology subtypes], performance status score [0-1 vs 2], study centre, or smoking status [never smokers vs smokers]) to receive intravenously 500 mg/m(2) pemetrexed plus 75 mg/m(2) cisplatin with (PCB) or without (PC) 15 mg/kg bevacizumab in 21 day cycles for up to six cycles, until progression or toxic effects. The primary outcome was overall survival (OS) in the intention-to treat population. Treatment was open label. This IFCT-GFPC-0701 trial is registered with ClinicalTrials.gov, number NCT00651456. FINDINGS From Feb 13, 2008, to Jan 5, 2014, we randomly assigned 448 patients to treatment (223 [50%] to PCB and 225 [50%] to PC). OS was significantly longer with PCB (median 18·8 months [95% CI 15·9-22·6]) than with PC (16·1 months [14·0-17·9]; hazard ratio 0·77 [0·62-0·95]; p=0·0167). Overall, 158 (71%) of 222 patients given PCB and 139 (62%) of 224 patients given PC had grade 3-4 adverse events. We noted more grade 3 or higher hypertension (51 [23%] of 222 vs 0) and thrombotic events (13 [6%] of 222 vs 2 [1%] of 224) with PCB than with PC. INTERPRETATION Addition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease. FUNDING Intergroupe Francophone de Cancérologie Thoracique (IFCT).
This paper references
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
Interpreting the signifi cance of changes in health - related qualityoflife scores
D Osoba (1998)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1097/JTO.0b013e318229586e
Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509
L. Garland (2011)
10.1053/J.AJKD.2006.11.039
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
X. Zhu (2007)
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer
M. Dong (2006)
10.1200/JCO.1998.16.1.139
Interpreting the significance of changes in health-related quality-of-life scores.
D. Osoba (1998)
10.1002/SIM.4780100609
Multiple testing in clinical trials.
P. Bauer (1991)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1200/JCO.2006.09.6305
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
B. Giantonio (2007)
10.1002/path.824
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
Adapting the Lung
PJ Hollen
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2007.14.5466
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
M. Reck (2009)
10.1080/1120009X.1990.11739003
Fluorouracil and leucovorin for metastatic colorectal cancer.
C. Erlichman (1990)
10.1097/JTO.0b013e318269fe21
Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma
Z. Labby (2012)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
cation criteria for patients with malignant pleural mesothelioma
MJ Byrne (2012)
10.2307/2530245
A multiple testing procedure for clinical trials.
P. C. O'Brien (1979)
Randomized Trials Stopped Early for Benefit
V. Montori (2007)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1200/JCO.2008.21.6630
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
R. Gray (2009)
uorouracil, and leucovorin for metastatic colorectal cancer
B Giantonio (2004)
10.1093/icvts/ivs542
What is the survival after surgery for localized malignant pleural mesothelioma?
Sandra Gelvez-Zapata (2013)
10.1200/JCO.2010.28.15_SUPPL.7020
IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma.
G. Zalcman (2010)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Phase II study of pemetrexed and carboplatin plus bevacizumab as fi rstline therapy in malignant pleural mesothelioma
GL Ceresoli (2013)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1002/cncr.20315
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma
P. Hollen (2004)
10.1002/sim.4431
Improper analysis of trials randomised using stratified blocks or minimisation.
B. Kahan (2012)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1097/JTO.0b013e3181ec18db
A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
S. Dubey (2010)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1097/JTO.0000000000000283
Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada
Sonya Cressman (2014)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)



This paper is referenced by
10.1007/s15033-019-1153-6
Multimodale Therapiekonzepte beim malignen Pleuramesotheliom
Laura V. Klotz (2019)
10.1245/s10434-018-6337-5
Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma
H. Alexander (2018)
10.1039/c8bm00225h
Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Run Lin (2018)
10.3390/cells9041019
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
Y. Nishinaga (2020)
10.1007/s00330-018-5533-9
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study
E. Gudmundsson (2018)
10.1158/1078-0432.CCR-19-0103
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
M. Okada (2019)
10.1016/j.lungcan.2019.12.018
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
Wei-Sen Lam (2019)
10.1186/s13045-019-0770-1
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
T. Liu (2019)
10.1007/978-3-319-53560-9_15
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
Mechanisms of TRAIL resistance
N. Kumar (2018)
10.1007/s00261-020-02535-1
Imaging spectrum of mesenteric masses
Radwan Diab (2020)
Méthylation du promoteur de RASSF1 et tunneling nanotubes : intérêt clinique dans les cancers pleuro-pulmonaires
Bastien Jean-Jacques (2019)
10.21037/tlcr.2018.04.09
Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review.
Lisa Brusselmans (2018)
10.1016/S1470-2045(18)30100-1
Novel therapies for malignant pleural mesothelioma.
A. Scherpereel (2018)
Nintedanib : new treatment for malignant pleural mesothelioma
(2017)
10.1080/14737140.2016.1191951
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges
G. Ceresoli (2016)
10.1038/s41573-018-0004-1
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen (2018)
10.3389/fonc.2017.00179
Oncolytic Viral Therapy for Mesothelioma
D. Pease (2017)
10.1016/j.jtho.2016.05.027
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
F. Facchinetti (2016)
10.2147/LCTT.S83338
Modern management of malignant pleural mesothelioma
S. Patel (2016)
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1183/13993003.00817-2018
Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks
J. Van Meerbeeck (2018)
10.2147/CLEP.S105396
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival
J. Beebe-Dimmer (2016)
10.3389/fonc.2020.588563
The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
O. Lauk (2020)
10.1016/S2213-2600(18)30151-6
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
L. Calabrò (2018)
10.1016/j.jtho.2018.10.005
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery
E. Harris (2019)
10.1016/j.jtocrr.2020.100075
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
Tamkin Ahmadzada (2020)
10.1186/s12904-017-0255-3
Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study
Anna C. Bibby (2017)
10.1016/j.ijheh.2017.09.013
Estimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening.
J. Cherrie (2018)
10.1007/978-3-030-16884-1_15
Role of Chemotherapy in the Management of Malignant Pleural Mesothelioma
L. Gianoncelli (2019)
10.21037/atm.2017.04.05
Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned.
D. Waller (2017)
10.1136/bmjresp-2017-000240
Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors
A. Kidd (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar